Targeting apoptosis defects in cutaneous T-cell lymphoma

Journal of Investigative Dermatology

Volumn 129, Issue 5, 2009, Pages 1059-1061

  Contassot, E ^a   French, Lars E ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INHIBITOR; FAS ANTIGEN; FAS LIGAND; HISTONE DEACETYLASE INHIBITOR;

APOPTOSIS; CUTANEOUS T CELL LYMPHOMA; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; LYMPHOMA CELL; NONHODGKIN LYMPHOMA; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 65249094257     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.14     Document Type: Note

References (10)

1. Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Durkop H et al. (2007) Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest Dermatol 127:2425-37
2. Chen J, Fiskus W, Eaton K, Fernandez P, Wang Y, Rao R et al. (2008) Co-treatment with BCL-2 antagonist sensitizes cutaneous T cell lymphoma to lethal action of HDAC7-Nur77 based mechanism. Blood; e-pub ahead of print 12 December 2008.
3. Contassot E, Kerl K, Roques S, Shane R, Gaide O, Dupuis M et al. (2008) Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood 111:4780-7
4. Dereure O, Portales P, Clot J, Guilhou JJ (2000) Decreased expression of Fas (APO-1/CD95) on peripheral blood CD4+ T lymphocytes in cutaneous T-cell lymphomas. Br J Dermatol 143:1205-10
5. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A (1999) The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 190:1025-32
6. Dutton A, O'Neil JD, Milner AE, Reynolds GM, Starczynski J, Crocker J et al. (2004) Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc Natl Acad Sci USA 101:6611-6
7. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A et al. (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347-9
8. Watanabe K, Okamoto K, Yonehara S (2005) Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 12:10-8
9. Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS Wood (2009) Low FAS/CD95 Expression by CTCL Correlates with Reduced Sensitivity to Apoptosis that Can Be Restored by FAS Upregulation. J Invest Dermatol 129:1165-73.
10. Zhang CL, Kamarashev J, Qin JZ, Burg G, Dummer R, Dobbeling U (2003) Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells. J Pathol 200:249-54 Zoi-Toli O, Vermeer MH, De Vries E, Van Beek P, Meijer CJ, Willemze R (2000) Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 143:313-9